A prognostic model for overall survival in sporadic Creutzfeldt-Jakob disease.
biomarker
cerebrospinal fluid
neurodegeneration
prognosis
sporadic Creutzfeldt-Jakob disease
tau
Journal
Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
09
01
2020
revised:
23
04
2020
accepted:
19
05
2020
pubmed:
3
7
2020
medline:
28
9
2021
entrez:
3
7
2020
Statut:
ppublish
Résumé
We developed a prognostic model for overall survival after diagnosis of sporadic Creutzfeldt-Jakob disease (sCJD) using data from a German surveillance study. We included 1226 sCJD cases (median age 66 years, range 19-89 years; 56.8% women with information on age, sex, codon 129 genotype, 14-3-3 in the cerebrospinal fluid (CSF), and CSF tau concentrations. The prognostic accuracy for overall survival was measured by the c statistics of multivariable Cox proportional hazard models. A score chart was derived to predict 6-month survival and median survival time. A model containing age, sex, codon 129 genotype, and CSF tau (with two-way interactions) was selected as the model with the highest c statistic (0.686, 95% confidence interval: 0.665-0.707) in a cross-validation approach. We developed the first prognostic model for overall survival of sCJD patients based on readily available information only. The developed score chart serves as a hands-on prediction tool for clinical practice.
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1438-1447Informations de copyright
© 2020 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
Références
Heinemann U, Krasnianski A, Meissner B. Creutzfeldt-Jakob disease in Germany: a prospective 12-year surveillance. Brain. 2007;130:1350-1359.
Zerr I, Parchi P. Sporadic Creutzfeldt-Jakob disease. Handb Clin Neurol. 2018;153:155-174.
Zerr I, Kallenberg K, Summers DM, et al. Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain. 2009;132:2659-2668.
Puoti G, Bizzi A, Forloni G, Safar JG, Tagliavini F, Gambetti P. Sporadic human prion diseases: molecular insights and diagnosis. Lancet Neurol. 2012;11:618-628.
Pocchiari M, Puopolo M, Croes EA, et al. Predictors of survival in sporadic Creutzfeldt-Jakob disease and other human transmissible spongiform encephalopathies. Brain. 2004;127:2348-2359.
Puopolo M, Ladogana A, Almonti S, et al. Mortality trend from sporadic Creutzfeldt-Jakob disease (CJD) in Italy, 1993-2000. J Clin Epidemiol. 2003;56:494-499.
Staffaroni AM, Kramer AO, Casey M, et al. Association of blood and cerebrospinal fluid tau level and other biomarkers with survival time in sporadic Creutzfeldt-Jakob disease. JAMA Neurol. 2019;76:969.
Llorens F, Karch A, Golanska E, et al. Cerebrospinal fluid biomarker-based diagnosis of sporadic Creutzfeldt-Jakob disease: a validation study for previously established cutoffs. Dement Geriatr Cogn Disord. 2017;43:71-80.
Karch A, Hermann P, Ponto C, et al. Cerebrospinal fluid tau levels are a marker for molecular subtype in sporadic Creutzfeldt-Jakob disease. Neurobiol Aging. 2015;36:1964-1968.
Llorens F, Kruse N, Karch A, et al. Validation of α-synuclein as a CSF biomarker for sporadic Creutzfeldt-Jakob disease. Mol Neurobiol. 2018;55:2249-2257.
Zerr I, Schmitz M, Karch A, et al. Cerebrospinal fluid neurofilament light levels in neurodegenerative dementia: evaluation of diagnostic accuracy in the differential diagnosis of prion diseases. Alzheimer's Dement. 2018;14:751-763.
Blennow K, Diaz-Lucena D, Zetterberg H, et al. CSF neurogranin as a neuronal damage marker in CJD: a comparative study with AD. J Neurol Neurosurg Psychiatry. 2019;90:846-853.
Steyerberg EW, Vickers AJ, Cook NR, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology. 2010;21:128-138.
Parchi P, Giese A, Capellari S, et al. Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol. 1999;46:224-233.
Zerr I, Bodemer M, Gefeller O, et al. Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt-Jakob disease. Ann Neurol. 1998;43:32-40.
Windl O, Giese A, Schulz-Schaeffer W, et al. Molecular genetics of human prion diseases in Germany. Hum Genet. 1999;105:244-252.
Hughes RA, Heron J, Sterne JAC, Tilling K. Accounting for missing data in statistical analyses: multiple imputation is not always the answer. Int J Epidemiol. 2019;48:1294-1304.
Therneau TM, Grambsch TM. Modeling Survival Data: Extending the Cox Model. New York: Springer; 2000.
Mogensen UB, Ishwaran H, Gerds TA. Evaluating random forests for survival analysis using prediction error curves. J Stat Softw. 2012;50:1-23.
Antolini L, Nam B-H, D'Agostino RB. Inference on correlated discrimination measures in survival analysis: a nonparametric approach. Commun Stat - Theory Methods. 2004;33:2117-2135.
Saarela O, Havulinna AS, Validstats: various prediction model validation statistics. R package version 1.4; 2017.
Benjamini Y, Hochberg Y. Controlling the false discovery rate-a new and powerful approach to multiple testing. J R Stat Soc B. 1995;57:289-300.
Harrell FE, {rms}: Regression Modeling Strategies. R package version 5.1-3.1; 2019. https://CRAN.Rproject.org/package=rms
Harrell FE. Regression Modeling Strategies: With Applications to Linear Models, Logistic regression, and Survival Analysis. 2nd ed. New York: Springer; 2015.
Zhang Z, Kattan MW. Drawing Nomograms with R: applications to categorical outcome and survival data. Ann Transl Med. 2017;5:211-211.
Jalali A, Alvarez-Iglesias A, Roshan D, Newell J. Visualising statistical models using dynamic nomograms. PLoS One. 2019;14:1-15.
Austin PC, Lee DS, D'Agostino RB, Fine JP. Developing points-based risk-scoring systems in the presence of competing risks. Stat Med. 2016;35:4056-4072.
Ban J-W, Stevens R, Perera R. Predictors for independent external validation of cardiovascular risk clinical prediction rules: cox proportional hazards regression analyses. Diagnostic Progn Res. 2018;2:1-9.
Schmitz M, Ebert E, Stoeck K, et al. Validation of 14-3-3 protein as a marker in sporadic Creutzfeldt-Jakob disease diagnostic. Mol Neurobiol. 2016;53:2189-2199.
Steyerberg EW, Harrell FE. Prediction models need appropriate internal, internal-external, and external validation. J Clin Epidemiol. 2016;69:245-247.